Navigation Links
Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
Date:4/21/2009

t Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts

    Steve Harris                 Rob Budge
    CEO                          RJB Communications
    Circassia Tel:                       +44-(0)1865-760969
    Tel: +44-(0)1865-784574      Mobile: +44-(0)7710-741241


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
4. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
5. Study Says Allergy Shots Help Children, Reduce Health Care Costs
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
9. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
10. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 4, 2012 /PRNewswire-iReach/ -- MediGain, a ... analytics, today announced the release of OptimOncology, a ... financial costing for office-based oncology practices.  This unique ... and provides measurable results for oncology practices. ...
... 2012 /PRNewswire-iReach/ -- Semantelli Corporation announced ... chosen Semantelli,s CoProtect® to manage its online ... life sciences industries, first compliance ready, actionable ... http://photos.prnewswire.com/prnh/20120104/CG30171 ) Semantelli,s compliance ready, ...
Cached Medicine Technology:MediGain Announces Release of New Oncology Analytics Solution 2Global Pharma Selects Semantelli's Compliance Ready Social Listening Platform to Manage Corporate Reputation 2
(Date:4/23/2014)... tract has long been considered to be between 180 ... have used refined microscopic techniques that indicate a much ... gastro-intestinal tract is only as large as a normal ... tract, which passes from the mouth through the esophagus ... about 5 meters in a normal adult, and is ...
(Date:4/23/2014)... doctors predict which patients might suffer potentially fatal side-effects ... which assesses brain scans using pattern recognition software similar ... has been developed by researchers at Imperial College London. ... Trust, which used the software are published in the ... over 15 million people each year worldwide. Ischemic strokes ...
(Date:4/23/2014)... American Gastroenterological Association (AGA) Research Foundation is pleased ... AGA Research Scholar Awards program, launched in 1984, ... research careers in digestive diseases. This year, the ... allowing for three consecutive years of funding. , ... are paving the way for promising research developments ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... 21, 2014 Five for-profit and non-profit organizations ... million in Proof of Concept grants to accelerate ... commercial products, the Life Sciences Discovery Fund (LSDF) ... Mentoring Program grant to the Washington Biotechnology & ... network to train the next generation of entrepreneurs ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... Mich., April 24 The Perrigo Company,(Nasdaq: PRGO ... from the,U.S. Food and Drug Administration (FDA) to market ... 4 mg (base) (Orange, Coated)., The FDA has ... drug, GlaxoSmithKline,s Nicorette(R) Gum, 2 mg (base) and 4 ...
... Courage Center is hosting a,credentialed educational forum on ... Golden Valley Road. The session offers three CEUs, ... Worker." Registration is from,8-8:30am with the session itself ... Golden Valley., Session participants will gain a ...
... LOUISVILLE, Ky., April 24 Ventas, Inc. (NYSE:,VTR) ... its May,19, 2008 annual meeting of shareholders, the Company,s ... $10 billion NYSE-listed real estate investment trust with assets,in ... Chicago as our,headquarters will provide the Company with increased ...
... difference after 65, study finds , , THURSDAY, April 24 (HealthDay News) ... money, appears to apply to the risk of stroke, a new ... stroke between the ages of 50 and 64, according to the ... Michigan Health and Retirement Study. , And the most probable reason ...
... WEST CHESTER, Ohio, April 24 Employees at ... a voluntary program,designed to promote healthy lifestyles. Modeled after ... salaried employees began a,12-week weight-loss contest in January -- ... a combined 4,256 pounds -- more than two tons ...
Cached Medicine News:Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2Health News:Ventas Names Chicago as Headquarters 2Health News:Ventas Names Chicago as Headquarters 3Health News:Ventas Names Chicago as Headquarters 4Health News:Ventas Names Chicago as Headquarters 5Health News:Higher Wealth Linked to Lower Risk of Early Stroke 2Health News:Higher Wealth Linked to Lower Risk of Early Stroke 3Health News:AK Steel Employees Compete for the Health of It 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: